Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Plasma cell 3Other hematologic neoplasm 2Thoracic 1Other solid neoplasm 1Other neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 508Uterine Cervical Neoplasms 361Endometrial Neoplasms 305Breast Neoplasms 130Colorectal Neoplasms 112Neoplasms 98Fallopian Tube Neoplasms 90Carcinoma, Non-Small-Cell Lung 87Stomach Neoplasms 83Pancreatic Neoplasms 79Lung Neoplasms 72Melanoma 68Prostatic Neoplasms 67Carcinoma, Ovarian Epithelial 65Neoplasm Metastasis 63Triple Negative Breast Neoplasms 51Vulvar Neoplasms 50Squamous Cell Carcinoma of Head and Neck 49Head and Neck Neoplasms 45Esophageal Neoplasms 43Uterine Neoplasms 40Peritoneal Neoplasms 40Urinary Bladder Neoplasms 38Carcinoma, Hepatocellular 35Carcinoma, Renal Cell 34Uterine Cervical Dysplasia 31Sarcoma 31Papillomavirus Infections 31Colonic Neoplasms 31Recurrence 29

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immunoproliferative Disorders × Gynecologic × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡